跳至主要内容
临床试验/JPRN-UMIN000020302
JPRN-UMIN000020302已完成未知

Efficacy and Safety of Ombitasvir plus Paritaprevir/r combination regimen for Hepatitis C infected patients with immune disorders - Ombitasvir /Paritaprevir/r therapy for patients with immune disorders

Hokkaido University0 个研究点目标入组 50 人开始时间: 2015年12月24日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Patients with poorly controlled cardiac disease (e.g., myocardial infarction, cardiac failure, arrhythmia) 2)Patients with severe hepatic impairment 3)Patients with a history of hypersensitivity to HCV protease inhibitors or NS5A inhibitor 4)Patients with a concurrent malignancy, including hepatocellular carcinoma, at the start of treatment 5)Patients deemed unsuitable for study entry by their treating physician 6)Patients who are unsuitable, in the opinion of the principal investigator, for this study due to any other reason

研究者

相似试验